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Background: Transmyocardial  laser revascularization was used as the sole 
therapy for patients with ischemic heart disease not amenable to percutaneous 
transluminal coronary angioplasty or coronary artery bypass grafting. This 
technique uses a carbon dioxide laser to create transmyocardial channels for 
direct perfusion of the ischemic heart. Methods: Since 1992, 200 patients, at 
eight hospitals in the United States, have undergone transmyocardial l ser 
revascularization. The patients have a combined 1560 months of follow-up for 
an average of 10 _+ 3 months per patient. Their age was 63 -+ 10 years and their 
ejection fraction was 47% + 12%. Eighty-two percent had at least one previous 
bypass graft operation and 38% had a prior angioplasty. Preoperatively, the 
patients underwent nuclear single photon emission computed tomography 
perfusion scans to identify the extent and severity of their ischemia. These 
scans were repeated at 3, 6, and 12 months. Angina class, admissions for 
angina, and medications were recorded. Results: The perioperative mortality 
was 9%. Angina class decreased significantly from before treatment to 3, 6, and 
12 months (p < 0.001). Likewise, there was a significant decrease in the 
number of perfusion defects in the treated left ventricular free wall. Concom- 
itantly, there was a significant decrease in the number of admissions for angina 
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in the year after the procedure when compared with the year before 
treatment (2.5 vs 0.5 admissions per patient-year). Conclusion: These 
combined results indicate that transmyocardial aser revascularization 
provides angina relief, decreases hospital admissions, and improves per- 
fusion in patients with severe coronary artery disease. (J Thorac Cardio- 
vasc Snrg 1997;113:645-54) 
T ransmyocardial laser revascularization (TLR) is a new technique that creates transmural channels 
in ischemic myocardium via laser ablation. Concep- 
tually, this allows direct perfusion of the myocardinm 
with ventricular blood. Since 1992, eight medical cen- 
ters in the United States have used a high-powered 
carbon dioxide laser to perform TLR. Several previous 
reports have investigated the use of this technique 
both clinically and experimentally. 1-19 The ability of 
TLR alone to provide relief of angina and improve 
myocardial perfusion was assessed in a cohort of 
patients with disabling angina refractory to medical 
therapy and untreatable by conventional means of 
revascularization. 
Patients and methods 
Between August 1992 and July 1995, 200 patients were 
treated with TLR at the following institutions: Seton 
Medical Center, San Francisco; St. Luke's Hospital, Mil- 
waukee; Brigham and Women's Hospital, Boston; Texas 
Heart Institute, Houston; Audubon Regional Medical 
Center, Louisville; University of Pittsburgh Medical Cen- 
ter, Pittsburgh; Rush-Presbyterian-St. Luke's Medical 
Center, Chicago; and Columbia Presbyterian Medical 
Center, New York. The study was approved by the Food 
and Drug Administration and by the institutional review 
boards at the aforementioned centers. Informed consent 
was obtained from each patient enrolled. 
Patient selection and demographics. Inclusion criteria 
for the study were threefold: (1) severe angina refractory 
to medical therapy, (2) reversible ischemia documented by 
a radionuclide myocardial perfusion scan, and (3) contra- 
indications to percutaneous transluminal coronary angio- 
plasty (PTCA), coronary artery bypass grafting (CABG), 
or transplantation. 
The patient demographics are outlined in Table I. The 
distribution of patients according to preoperative angina 
class is depicted in Fig. 1, A. Preoperatively, 80% of the 
patients were in Canadian angina class IV and 20% were 
in class III. 
Radionuclide scans. Preoperatively, all the patients un- 
derwent rest and stress nuclear medicine perfusion scans to 
assess the extent and reversibility of their myocardial isch- 
emia. The scans were obtained with the use of thallium 201 
or technetium 99m sestamibi. A 2 to 3 mCi dose of 2°1T1 was 
administered atpeak stress, and stress images were obtained 
15 minutes later. Redistribution images were obtained at 34 
hours followed by reinjection of half the stress dose in cases 
Table I. Patient demographics 
Men 156 78% 
Women 44 22% 
Age (yr) 
Mean _+ SD 63 _+ 10 
Range 35-85 
Diabetes 69 35% 
Hypertension 133 67% 
Cholesterol > 200 mg/dl 131 65% 
Unstable angina 178 89% 
Previous MI 155 78% 
Previous PTCA 56 38% 
Previous CABG 164 82% 
Ejection fraction (%) 
Mean +_ SD 45 + 10 
Range 15-75 
M/, Myocardial infarction; SD, standard deviation. 
in which the redistribution images were abnormal. 99mTc 
sestamibi imaging was performed according to the rest-stress 
protocol, in which 7 to 9 mCi 99mTc sestamibi isadministered 
at rest with rest imaging 45 to 60 minutes later, followed by 
administration f21 to 25 mCi 99mTc sestamibi at peak stress 
and stress imaging 30 to 60 minutes later. 
Symptom-limited treadmill stress testing was performed 
in the preoperative period by means of the Bruce proto- 
col. Postoperative stress testing was done with the use of 
the same protocol and to the same rate-pressure product 
as before the operation. The standard ipyridamole pro- 
tocol was used for pharmacologic stress testing: 0.56 mg 
dipyridamole infused intravenously over 4 minutes and 
tracer administration 4 minutes after termination of the 
infusion. 
Single photon emission computed tomographic imaging 
was performed according to institutional protocols for all 
patients. The data were reconstructed with filtered back- 
projection and reformatted into coronal, sagittal, and 
transaxial slices. Corresponding rest and stress coronal- 
sagittal-transaxial d ta were generated and transferred to 
hard copies. 
All studies were read by two observers m a central core 
laboratory. The observers were blinded to patient infor- 
mation. The observers did not know whether a given study 
was was conducted before or after the operation, and the 
results of prior studies were unknown. Differences be- 
tween observers were resolved by consensus. 
The left ventricular free wall was divided into twelve 
segments. There are an additional twelve segments in the 
septum and one in the apex. Segments with abnormal 
uptake at rest were scored as having a fixed perfusion 
defect (i.e., scar). Segments with decreased tracer uptake 
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Fig. 1. A, Preoperative angina class. B, Angina class at 3 months. 
during stress compared with rest were scored as having 
reversible perfusion defect (i.e., ischemia). The number of 
segments with fixed perfusion defects and the number of 
segments howing reversible defects were tabulated for 
the septum (nontreated portion of the myocardium) and 
for the left ventricular free wall (treated portion). 
Operative technique. The patients were intubated and 
a transesophageal echocardiography (TEE) probe was 
inserted. A baseline TEE study was performed to evaluate 
ventricular function and valvular disease. The TEE was 
primarily used to confirm transmyocardial penetration of 
the laser beam. The patients were placed in a 45-degree 
right lateral decubitus position and underwent a left 
anterolateral thoracotomy through the fifth or sixth inter- 
costal space depending on the location of the point of 
maximal impulse. The pericardium was opened and dis- 
sected free of the heart. In patients status post-CABG, 
care was taken to avoid previous bypass grafts. On the 
basis of the preoperative nuclear medicine scan, the area 
of reversible ischemia was exposed. 
Laser. The laser is a 1000 watt carbon dioxide device 
(The Heart Laser, PLC Medical Systems, Milford, Mass.) 
that delivers 850 watts of peak power to the tissue. The 
maximum output is 80 joules and the pulse width can be 
varied from 1 to 99 msec. The operative settings were an 
average pulse energy of 42 _+ 10 joules and a pulse width 
of 52 + 12 msec. The carbon dioxide laser is aimed with 
helium-neon laser guidance, placed against the epicar- 
dium, and fired. The laser is triggered to fire on the r wave 
of the electrocardiographic cycle when the ventricle is 
maximally distended with blood and electrically quiescent. 
The laser energy is absorbed by the blood in the ventricle, 
and this produces an acoustic image analogous to steam 
that is readily visible by TEE in the long-axis four- 
chamber view. This TEE image denotes transmyocardial 
penetration. Only laser shots verified by TEE were con- 
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Fig. 1. C, Angina class at 6 months. D, Angina class at 12 months. 
sidered to have traversed the myocardium. On average 
30 - 12 pulses were delivered and 25 _+ 9 were confirmed 
by TEE for each case. The channels are 1 mm in diameter 
and were created in a distribution of approximately one 
per square centimeter. Hemorrhage from the channels 
was controlled with direct finger pressure or an epicardial 
suture if pressure was not adequate. 
Follow-up. The 200 patients combined for 1560 pa- 
tient-months of follow-up. The average length of fol- 
low-up was 10 2 3 months. The patients returned at 3, 
6, and 12 months after the operation for physical 
examination, review of medications, and assessment of 
angina class. Baseline radionuclide scans were required 
for preoperative valuation. Additional radionuclide 
scans were obtained at 3, 6, and 12 months according to 
individual institutional protocols of follow-up. At a 
given month of follow-up assessments (3, 6, or 12 
months), only patients with complete data for that 
particular month contributed ata to the analysis. An- 
gina class data were complete for 156 patients at 3 
months, 143 patients at 6 months, and 95 patients at 12 
months. Radionuclide studies were complete for 120, 
107, and 59 patients at 3, 6, and 12 months, respectively. 
The follow-up studies were compared with the preop- 
erative baseline scans, and the change in the number of 
involved segments was calculated. The septum was not 
treated by TLR and thereby served as a control for each 
patient. Angina class, medications, activity level, and 
admissions for angina were assessed by interview and 
questionnaire. 
Statistics. Angina class at baseline and follow-up was 
compared with the use of the Wilcoxon signed rank test 
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Fig. 2. Survival after TLR. 
and paired t test. Differences were considered significant 
at p < 0.05. When necessary, a Bonferroni correction for 
repeated measures at multiple time points was used. The 
p values listed are two-sided p values. Results are ex- 
pressed as mean -+ standard eviation. 
Results 
Morbidity. Postoperative morbidity from the 
procedure was minimal. No intraoperative laser- 
induced arrhythmias occurred. There was a 9% 
incidence of atrial fibrillation after the operation (18 
patients). Four patients had myocardial infarctions 
(2%). One patient had acute mitral regurgitation as 
a result of laser injury of the chordae and underwent 
mitral valve repair at the time of the procedure. Two 
patients (1%) required reoperation for bleeding. 
Intraaortic balloon pump assistance was used after 
the operation in seven patients (4%). One wound 
infection occurred and five cases of pneumonia 
(2.5%). The majority of the patients were extu- 
bated within the first 24 hours after the operation 
(0.8 + 1.4 days). The average intensive care unit 
stay was 2 _+ 3 days. The average hospital stay was 
8 _ 6 days. 
Mortality. Eighteen (9%) deaths occurred in the 
first 30 days after the procedure. The causes of 
death for these patients are listed in Table II. The 
majority of these deaths (12) were cardiac in nature. 
All of these patients had class IV unstable angina in 
the preoperative period. Fifteen of these patients 
had had a previous CABG. Autopsies were per- 
Table II. Deaths  
Cause No. of patients 
Early deaths 
Myocardial ischemia 5 
Myocardial failure 5 
Sudden death 2 
Multisystem organ failure 2 
Pulmonary embolism 1 
Gastrointestinal bleeding 1 
Pneumonia 1 
Anesthetic complication 1 
Late deaths 
Myocardial ischemia 1 
Myocardial failure 4 
Sudden death 2 
PTCA 2 
Heart transplant 1 
House fire 1 
Unknown 6 
formed in eight of the patients and determined the 
cause of death as listed. 
Over the subsequent months of follow-up an 
additional 17 (9%) deaths occurred, ranging from 
postoperative day 33 to day 317. The causes of these 
late deaths are listed in Table II. Of these deaths, 
seven were related to the heart. Fig. 2 depicts the 
postoperative survival for all patients after TLR. 
Thirteen of the patients had additional proce- 
dures in the 12 months after their TLR. Three 
patients died as a result of these procedures and are 
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Fig. 3. A, Left ventricular f ee wall perfusion. B, Septal perfusion. 
listed in Table II. The remaining 10 patients under- 
went the following procedures: one re-TLR (356 
days after TLR), three CABGs (106, 126, and 326 
days after TLR), and six PTCAs (2, 24, 111, 217, 
301, and 313 days after TLR). Data on patients after 
additional revascularization procedures were not 
included for analysis. 
Medications. All patients were initially restarted 
on their preoperative medications immediately 
after their TLR. One year after TLR, 56% of the 
patients had decreased their usage of cardioactive 
medications (nitrates, /3-blockers, or calcium 
channel blockers) and 19% had increased their 
medications• 
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Hospital admissions. In the year before their 
TLR, the patients averaged 2.5 _ 2 admissions for 
angina. In those patients with a full year of follow-up 
there was a significant decrease in the number of 
admissions, with an average of 0.4 ___ 0.6 admissions 
for angina after treatment with TLR (p < 0.001). 
Angina class. Angina class decreased signifi- 
cantly from the preoperative status at 3, 6, and 12 
months (p < 0.001). The distribution of patients 
according to Canadian angina class at baseline and 
at 3, 6, and 12 months of follow-up is depicted in 
Fig. 1, A to D. There was a significant redistribution 
of patients from angina class III and IV to a 
markedly decreased incidence of angina. In fact, for 
one third of the patients angina was eliminated and 
did not recur throughout the average 10 ___ 3 months 
of follow-up. Using the definition that a decrease of 
two angina classes after the operation is considered 
a success, the procedure had a 75% success rate for 
patients at 3 months (117/156 patients, p < 0.001), at 
6 months (108/143 patients, p < 0.001), and at 12 
months (70/95 patients, p < 0.001). 
Radionuclide peffusion scans. The results of the 
preoperative and postoperative radionuclide perfu- 
sion scans are graphically displayed in Fig. 3, A and 
B. A significant decrease in the number of segments 
with reversible perfusion defects in the treated left 
ventricular free wall was noted at 6 and 12 months 
(Fig. 3,A). With this change there was no increase in 
the number of segments with fixed defects in the 
treated area. Results of scans of the untreated 
septum (Fig. 3, B) reveal no significant change in 
either the fixed or reversible perfusion defects. 
Positron emission tomographic scans. One insti- 
tution (THI) performed positron emission tomo- 
graphic scans before and after the operations. These 
confirmed improved subendocardial versus subepi- 
cardial resting perfusion in the laser-treated areas at 
12 months (0.96 _+ 0.07 vs. 1.10 _+ 0.04,p < 0.001, 
n = 11). 
Discussion 
The success of any type of myocardial revascular- 
ization is the improvement in the delivery of oxygen- 
carrying blood to the ischemic area. This has been 
achieved by manipulation of the existing coronary 
vasculature by CABG and PTCA. Unfortunately, 
these conventional methods of revascularization 
cannot be used in a significant number of patients. 
These patients may have diffusely small vessels or 
may have already exhausted their ability to undergo 
another PTCA or CABG. It is for these patients that 
TLR was developed. 
Before the advent of PTCA and CABG, attempts 
were made at direct transmyocardial revasculariza- 
tion. 2°-27 A series of tubes and needles to create 
transmural channels were used with minimal suc- 
cess. 22-z7 Conceptually, these methods were based 
on the knowledge of myocardial sinusoids and the 
thebesian system. 28 These communications were 
thought o allow direct perfusion of the myocardium 
by ventricular blood. Other methods of creating 
myocardial neovascularization by omentopexy and 
poudrage or by internal thoracic artery implantation 
were also moderately successful. 2°' 21 TLR incorpo- 
rates the direct perfusion and neovascularization f 
these other techniques. Although the exact mecha- 
nism of TLR is unknown, there appears to be 
evidence of channel patency and of angiogene- 
sis.l, 4, 7, 9, 14, 15 In theory, the laser-created channels 
would provide blood to the myocardium and stimu- 
late further vessel formation. This process would 
take some time and may explain the improvement in 
angina class and perfusion scan results, particularly 
between 3 and 6 months after the operation. This 
improvement persists for 1 year after the procedure. 
The possibility that this is due to a placebo effect 
may be a criticism of the angina class data but 
cannot explain the improved perfusion as seen by 
single photon emission computed tomography and 
positron emission tomographic scans. 
Symptomatically, the patients have shown initial 
improvement, which has continued with time. In 
addition to a significant decrease in their angina 
class, they have been able to avoid readmissions to 
the hospital for angina and have decreased their 
medication usage. 
Limitations. This study, albeit prospective, does 
not have a randomized control group. On the basis 
of these preliminary results of this study, two sepa- 
rate multiinstitutional randomized controlled trials 
are in progress comparing TLR versus medical 
management and TLR versus reoperative CABG. 
These studies are still accruing patients and the 
results are pending. 
The protocols for radionuclide myocardial perfu- 
sion scans varied among the participating institu- 
tions but were consistent with regard to the individ- 
ual patient. Identical protocols at all sites are being 
applied in the ongoing randomized controlled trial. 
Another limitation is the additional procedures 
that 13 of the 200 patients underwent after their 
TLR. Unfortunately, several of these procedures 
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were performed at institutions outside the study 
group. These additional procedures demonstrate 
the difficulty in treating these patients, inasmuch as 
they resulted in three deaths. Patients who survived 
these procedures were not included in the follow-up 
because the goal was to evaluate the efficacy of TLR 
in treating their disease. This was not a study to 
determine the benefit of TLR in combination with 
another method of revascularization. Assuming the 
worst case scenario, that is, that all of these patients 
were in angina class IV at the time of their proce- 
dure and remained in that class for the duration of 
follow-up, there was no significant change in the 
success rate of the procedure at 3 (p < 0.001), 6 (p < 
0.001), and 12 months (p < 0.001). 
This study was designed to observe the patients 
and collect data for 1 year. Some of the institu- 
tions have observed their subgroups of patients 
for longer periods and have reported continued 
relief of angina and improved perfusion. 6'16, 17 
The purpose of this report is to confirm the earlier 
individual reports in a significantly larger com- 
bined group of patients. Further follow-up will 
obviously allow evaluation of the long-term effi- 
cacy of the procedure. 
Future investigations experimentally include fur- 
ther elucidation of the mechanism and the use of 
angiogenic growth factors with TLR. Clinically, the 
greatest potential future use of TLR is in conjunc- 
tion with CABG. This would provide an adjunct o 
CABG in the patient in whom some territories are 
graftable and others are not. It can be performed 
thoracoscopically and would also provide a method 
to expand the areas revascularized during minimally 
invasive CABG. TLR may also prove beneficial in 
the treatment of the diffuse atherosclerosis seen in 
patients having heart transplantation. 
Conclusion 
The results of this multicenter t ial using TLR as 
sole therapy for severe angina indicate that TLR 
provides relief of angina and improves myocardial 
perfusion in patients with end-stage coronary artery 
disease. 
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Discussion 
Dr. John L. Ochsner (New Orleans, La.). This is an 
interesting paper in which the results of the procedure 
were designed to deliver blood to the myocardial sinu- 
soids, somewhat like the Vineberg operation. Also like the 
Vineberg operation, it carried a very significant mortality, 
just about the same, 9%, and had a similar 1-year success 
rate. However, after a Vineberg operation, one can ob- 
jectively demonstrate blood flow. If the internal thoracic 
artery is injected, it shows myocardial sinusoid blushing, 
and frequently even filling of the coronary arteries. How- 
ever, to the best of my knowledge, I have been unable to 
find any report of even a myocardial blush from a ven- 
triculogram after a transmyocardial revasacularization. In 
fact, except for a few anecdotal reports, we have been 
unable to demonstrate any long-term patency of the 
channels. Yet one cannot argue with the clinical success of 
the operation. What is the mechanism of the success? Is it 
perfusion of the sinusoids by ventricular blood? Is it 
perfusion that occurs from angiogenesis that is a result of 
a metabolic response in scar tissue? Is it laser destruction 
of neuron networks within the heart? Or is it just a 
placebo effect, what we in the deep bowels of Cajun 
country refer to as voodoo? Of course, these are only 
hypotheses; we cannot be sure of the source of its 
beneficial results. On the other hand, for years we did not 
know the exact mechanism of digitalis or aspirin, and yet 
we knew they were effective. 
We recently extended our indications for transmyocar- 
dial revascularization to include patients who had had 
transplantation. Recently, in one patient who required a 
CABG operation, we used the transmyocardial revascu- 
larization as an adjunct in the hope of treating the 
small-vessel disease known to occur with allograft vascu- 
lopathy. 
! would like to ask two questions of the authors. Do you 
have any long-term data, that is, over a year, particularly 
in regard to the control of angina? We have seen the 
angina disappear early only to recur late and then pro- 
gressively disappear again as we think angiogenesis oc- 
curs. Second, do you believe that we should start to 
include those patients who are in heart failure but without 
angina but do have evidence of hibernating myocardium? 
Dr. Gurukumar B. Parulkar (Bombay, India). Dr. Hor- 
vath and his colleagues have presented highly scientific 
data on patients who underwent transmyocardial revascu- 
larization during the multicenter clinical trial. In 1965 the 
late Dr. Sen and I reported a similar concept of transmyo- 
cardial revascularization in experimental nimals, using a 
large-bore needle to make through-and-through punc- 
tures in the anoxic left ventricle. It was interesting in those 
days to observe how these punctures, which did not 
remain patent after 6 to 8 weeks, could effectively reduce 
myocardial necrosis after ligation of the left anterior 
descending artery. We did use this technique occasionally 
in patients with accidental injury to the coronary arteries 
or to treat severe anoxic damage after anoxia during 
cardiac operations; however, we have never reported this 
work. 
I have one question for the authors. Have they thought 
of using transmyocardial revascularization in patients with 
cardiogenic shock with very advanced coronary artery 
disease in whom neither surgery nor angioplasty can be 
considered? 
Dr. Josef G. Vincent (Kreuzlingen, Switzerland). In a 
2-year period in our clinic we operated on 212 patients 
using the carbon dioxide laser, and I am extremely happy 
that our results may confirm your study on the other side 
of the ocean. The criteria to accept the patients were, 
without exception, refusal from other centers to operate 
on them or to do PTCA. The medical therapy was 
maximal. To our surprise, the patients were able to pass 
an exercise test 5 days after the operation. Our follow-up 
study, which contains 146 patients at 3, 6, and 12 months, 
reveals low grading of the angina class for at least two 
classes, inasmuch as 82% of our patients were in classes 
III and IV and now 75% and 89% are in class I or zero. 
We were not able to confirm these results on echography 
or on scintiscan on all of our patients, but the quality of 
life of our patients, voodoo or not, improved considerably. 
We are happy so far to greet the patients back, walking 
around, without any pain, and with lower medication 
doses. 
Dr. Todd Rosengart (New York, N.Y.). We have been 
looking at the excimer laser for performing TLR in recent 
studies in a sheep model. We created a series of excimer- 
lased channels. We were actually delivering about 1 joule 
of energy per channel and looked at histology at 30 days. 
Because there has been some question as to whether 
nonlased acupuncture might be an effective TLR tech- 
nique, we also created a series of nonlased channels with 
the fiberoptic delivery system that we were using. At 30 
days, 60% of the lased channels were patent and most of 
those demonstrated a well-lined endothelium. We also 
noticed, as have the investigators u ing the carbon dioxide 
laser, that there was a significant neovascular response in 
the lased segments. However, in contrast, none of the 
nonlased channels was patent at 30 days, and we saw very 
little in the way of a neovascularization response in these 
nonlased regions. 
Do you think that it is the laser energy delivered, the 
tissue vaporization, the adjacent issue injury, or some 
other effect that at the present ime we are not aware of 
that is causing the results that we are seeing with TLR? 
Dr. Horvath. All of these questions are very pertinent, 
and the majority concern the mechanism. This is an 
experimental technique, and the clinical results that we 
have seen are valid. I am not sure what the mechanism is, 
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whether it is, as Dr. Ochsner outlined and Dr. Rosengart 
echoed, due to perfusion directly from the ventricle into 
the myocardium, whether it is due to angiogenesis as a 
result of delivery of laser energy to the myocardium, or 
whether denervation plays a role in eliminating the angi- 
nal symptoms. 
Voodoo is something that I am not familiar with and I 
hope I never will be. With regard to the possible placebo 
effect, a similar study was done years ago by E. Grey 
Diamond. A number of patients underwent internal tho- 
racic artery ligation to relieve their angina. It is the only 
prospective randomized ouble blind study of the surgical 
treatment of angina. The patients were randomized into a 
placebo and a treated group. Unfortunately, at 9 months 
none of the patients in either group said that they were in 
fact angina-free. The fact that patients are free of symp- 
toms after 1 year of follow-up indicates that something 
beyond a placebo effect is occurring here. 
Regarding long-term follow-up, some of our patients 
were operated on 4 years ago, and their results are the 
same as they were at 1 year. 
As Dr. Rosengart has said, the laser has a major 
advantage over the needle in that there is actual tissue 
ablation and the delivery of laser energy. Both the work 
done by Dr. Sen, which was alluded to by Dr. Parulkar, 
and the study that Dr. Rosengart referred to using a 
needle or fiber demonstrates that a minimum effect can be 
obtained with these techniques, but the channels do not 
appear to stay patent. 
Finally, regarding the use of this procedure for heart 
failure, the criteria that we had established was that none 
of these patients hould be transplant candidates. In fact, 
in reviewing our data for the patients who died early, one 
of the independent risk factors was an ejection fraction 
less than 20%. Unless there is a significant area of 
hibernating myocardium or reversible ischemia delineated 
by the nuclear medicine scan, I cannot recommend this as 
a treatment for heart failure. 
In summary, a number of these questions will be 
answered with the ongoing trials approved by the Food 
and Drug Administration. There are presently twe ran- 
domized controlled studies, one comparing the laser to 
continued medical therapy and another comparing the 
laser to reoperative CABG. In the first study 113 of the 
150 patients have been enrolled and the initial 3-month 
results are encouraging, but further work is needed 
both clinically and experimentally to answer these 
questions. 
